

First Name: Tara
Last Name: Henderson
Institution: University of Chicago
Address 1: 5841 S. Maryland Ave.
Address 2:
City: Chicago
State/Province: IL
Country: USA
Zip: 60637
Phone: 773-702-2501
Alternate Phone: 773-573-7690
Email: thenderson@uchicago.edu

Requirements to submit AOI:

A comprehensive review of previously published data has been completed.: Yes
The specific aims are clear and focused.: Yes
The investigator has appropriate experience and expertise to develop the concept proposal; if not, has identified a mentor or senior co-investigator.: Yes
The investigator agrees to develop an initial draft of the concept proposal within 6 weeks of approval of the AOI and to finalize the concept proposal within 6 months.: Yes

Project Title: Improving delivery of genetic services to high risk childhood cancer survivors
Planned research population (eligibility criteria): Female sarcoma survivors who have not received chest RT and have not developed an SMN.
Proposed specific aims: Aim 1: 1a. To determine the efficacy of telemedicine to increase the uptake of cancer risk assessment (primary outcome; including genetic counseling and pedigree assessment) and genetic testing as compared to mailed education materials (highlighting value of cancer risk assessment and local resources). 1b. To evaluate potential modifiers of uptake of genetic services including socio-demographics, access, knowledge of primary cancer and risk of late effects, psychological adjustment, health behaviors, preference for delivery modality. Aim 2: To evaluate the short term and 12 month outcomes (patient knowledge and perceptions, psychological distress, satisfaction with genetic services, patient and system costs) of telegenetic-delivered cancer risk assessment for childhood cancer survivors. Aim 3: To evaluate the short and longitudinal outcomes of genetic testing (genetic test results, psychological adjustment, performance of health behaviors, satisfaction with mode of disclosure of results) in the subset of childhood cancer survivors who undergo genetic testing.
Will the project require non-CCSS funding to complete?: Yes
If yes, what would be the anticipated source(s) and timeline(s) for securing funding?: NCI R01 - October 2014 (Dissemination and Implementation RFA) ACS

Does this project require contact of CCSS study subjects for . . .

Additional self-reported information: Yes

Biological Samples: No

Medical record data: Yes

If yes to any of the above, please briefly describe.: This will be a randomized clinical trial with these women. Thus, recontact and MR review will be required.

What CCSS Working Group(s) would likely be involved? (Check all that apply)

Second Malignancy:

Chronic Disease:

Psychology / Neuropsychology:

Genetics: Primary

Cancer Control: Secondary

Epidemiology / Biostatistics:

To describe the anticipated scope of the study, please indicate the specific CCSS data to be included as outcome (primary or secondary) or correlative factors. (Check all that apply)

Late mortality:

Second Malignancy:

Health Behaviors

Tobacco:

Alcohol:

Physical activity:

Medical screening: Correlative Factors

Other:

If other, please specify:

Psychosocial

Insurance: Correlative Factors

Marriage: Correlative Factors

Education: Correlative Factors

Employment: Correlative Factors

Other:

If other, please specify:

Medical conditions

Hearing/Vision/Speech:

Hormonal systems:

Heart and vascular:

Respiratory:

Digestive:

Surgical procedures:
Brain and nervous system:
Other:
If other, please specify:

Medications

Describe medications:

Pregnancy and offspring:
Family History: Correlative Factors

Psychologic/Quality of Life

BSI-18:
SF-36:
CCSS-NCQ:
PTS:
PTG:
Other:
If other, please specify:

Chronic conditions (CTCAE v3):
Health status:

Demographic

Age: Correlative Factors
Race: Correlative Factors
Sex: Correlative Factors
Others:
If others, please specify:

Cancer treatment

Chemotherapy:
Radiation therapy:
Surgery:

Anticipated sources of statistical support

CCSS Statistical Center:

Local institutional statistician: Yes

If local, please provide the name(s) and contact information of the statistician(s) to be involved.:

Chaya Moskowitz, PhD Memorial Sloan Kettering Cancer Center

Will this project utilize CCSS biologic samples?: No

If yes, which of the following?

Buccal cell DNA:

Peripheral blood:

Lymphoblastoid cell lines:

Second malignancy pathology samples:

Other requiring collection of samples:

If other, please explain:

Other general comments: